MyFinsight
Home
Compare
About
Recent SEC Filings
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Income Overview
Revenue
$114,196K
Net Income
-$101K
Net Profit Margin
-0.09%
Unit: Thousand (K) dollars
Revenue Breakdown
Non Cash Royalty Revenue
Pre Commercial Product Revenue
Other
Clinical Product Revenue
Revenue Breakdown
Non Cash Revenue Related To Sale...
Pre Commercial Product Revenue
Revenue
Research And Development Revenue
Revenue Breakdown
US
Non Us
Subscribe for Financial Insights
Page 1
Annual
123
Page 1
Income Statement
2025-12-31
Total revenues
114,196
Cost of revenue
1,022
Research and development
79,338
General and administrative
54,392
Fair value adjustments
387
Operating loss
-20,169
Non-operating income (expense)
-2,220
Mink therapeutics, inc. equity method investment fair value adjustment
-26,345
Gain from deconsolidation of mink therapeutics, inc
100,924
Interest expense, net
-55,273
Net loss
-3,083
Dividends on series a-1 convertible preferred stock
216
Less net loss attributable to non-controlling interest
-3,198
Net loss attributable to agenus inc. common stockholders
-101
Basic EPS
0
Diluted EPS
0
Basic Average Shares
29,734,000
Diluted Average Shares
29,734,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS).
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
3
AGEN Income Statement Sankey Diagram
Sankey diagram visualizing AGEN income statement for the period
Net loss
attributable to agenus inc....
-$101K
Less net loss
attributable to...
-$3,198K
Revenue From Contract
With Customer...
$108,588K
Revenue From Contract
With Customer...
$4,238K
Revenue From Contract
With Customer...
$1,036K
Revenue From Contract
With Customer...
$334K
Net loss
-$3,083K
Gain from
deconsolidation of mink...
$100,924K
Dividends on series a-1
convertible preferred stock
$216K
Non Cash Royalty
Revenue
$108,588K
Pre Commercial
Product Revenue
$4,238K
Other
$1,036K
Clinical Product Revenue
$334K
Interest expense, net
-$55,273K
Mink therapeutics,
inc. equity method...
-$26,345K
Operating loss
-$20,169K
Non-operating income
(expense)
-$2,220K
Total revenues
$114,196K
Fair value
adjustments
$387K
Research and development
$79,338K
General and
administrative
$54,392K
Cost of revenue
$1,022K
Buy us a coffee
AGENUS INC (AGEN)
AGENUS INC (AGEN)